Maas BiolAB expands in Europe
HONOLULU--(BUSINESS WIRE)--June 28, 2001--Maas BiolAB, LLC, a privately-held
Swedish-American biopharmaceutical company, announced the formation of
its wholly owned Swedish subsidiary, NeuroPharma AB, and 3 appointments
to the international management team. NeuroPharma AB will be the vehicle
for Maas' European development of Cyclosporin Neuroprotection.
Gregory Batcheller, LL.M., Vice President Strategic Development
(Lund, Sweden).
Mr. Batcheller is a corporate lawyer focused on pharmaceutical, biotech and medical device clients with an emphasis on entrepreneurial, innovative businesses. He has lectured in intellectual property law and European Union competition at Lund University, where he obtained his LL.M. in European Law. Mr. Batcheller obtained his B.Sc. (Economics.) from the London School of Economics and his LL.B. from the University of Toronto. Batcheller was previously a partner of a major Canadian law firm, now merged into Borden Ladner Gervais. He is responsible for Maas corporate and business development, legal affairs, and project management.
Andreas Inghammar, LL.M., Director of Administration (Lund, Sweden).
Mr. Inghammar received his LL.M. from the University of Lund in 1998 and, through 1999, clerked at the Administrative Court of Skåne (South Sweden), in Malmö. He is lecturer and Ph.D. candidate in European Labour Law at the Faculty of Law, University of Lund, Sweden. He is a member of the board of research at the Faculty and president of the board for Ph.D. candidates. Mr. Inghammer will coordinate Maas operations in Scandinavia and Maas administration.
Philippe Racapé, MBA. Director of Finance (Paris, France).
Mr. Racapé has his MBA in International Business from Institut Supérieur de Gestion (ISG) in Paris with internships in USA, Japan, Hong Kong and P.R. China. He has worked in BNP-PARIBAS as corporate relations manager and in the Audit department. Mr. Racapé will be co-ordinating Maas operations in France, and the company's international financial development.
"I am excited by the skills and exceptional ability brought by these talented and driven gentlemen." said Dr. Marcus Keep, CEO. " Batcheller, Inghammar and Racapé possess legal, development and financial skills essential to the Maas management core. Their work is rapidly growing our startup multinational biopharma."
Helmuth von Moltke, Corporate Director remarked "Our management team is located in the major developed world pharmaceutical markets of Europe, and the United States. Our strategy is to raise capital from both markets to start cyclosporin Phase 2 human trials in traumatic brain injury, and the neurodegenerative diseases of ALS, Huntington's and Alzheimer's."
Eskil Elmér, Maas Scientific Director noted "Since joining Maas, Mr. Batcheller, along with Inghammar and Racapé, has brought several negotiations close to fruition in both Europe and the USA, including industry, and academic partnerships. The final piece required is capital investment to fuel taking our proprietary cyclosporin neuroprotection products to market in the shortest time."
Maas BiolAB has broad world patents for cyclosporin neuroprotection in
numerous brain diseases including Alzheimer's, Parkinson's, ALS, Huntington's,
HIV dementia, traumatic brain injury, and stroke. Cyclosporin is the most
powerful neuroprotectant so far seen in animal models because of its unique
effects as the mitochondrial pore blocker and neuroimmunophilin.
CONTACT:
North America:
Marcus Keep. M.D.
President and CEO
Maas BiolAB, LLC
mkeep@maasbiolab.com
+ 1-808-547-6940 tel
Europe:
Greg Batcheller
VP Strategic Development
Maas BiolAB, LLC
NeuroPharma AB
greg@maasbiolab.com
www.maasbiolab.com
+46-46-157763 tel
